Nyhet -

Very promising clinical results in new treatment of varicose veins

Established in 2013 by Dr Michael Åkesson, the company MedVasc was created to help his pursuit on improving the procedure of minimally invasive treatment in the condition of varicose vein. Michael has a long experience in developing and testing new catheters for endovascular techniques.

The earning potential of Solutio (which was patented in 2015) paved the way for additional investment and created the company MedVasc AB.

With a vision to launch a market-winning product that improves patients’ well-being and shorten the treatment procedure, MedVasc aims to make its product Solutio the standard treatment for anaesthesia in varicose vein treatment.

How does it work?

MedVasc introduces an innovative treatment procedure with only one cut through the patient’s skin and a single catheter introduced into their vein. It encloses both a laser fibre (or electrode in RFA) and an anaesthetic needle. Solutio operates the needle and punctures the vein wall to numb the surrounding tissue. Then, the ablation is performed on the anesthetized section. Anaesthesia will be administered from within the vein, eliminating the pain connected with the standard injections from the surface of the skin.

The surgery time is reduced by a half with no need for a special step for tumescent anaesthesia administration. The post-operative care is reduced to less than 15 min, so the overall stay at the clinic should not be longer than 1.5 h. In addition, the need for health care personnel monitoring the sedation will be reduced.

Promising results

Back in April 2020, MedVasc AB reported promising results from an initial clinical study in which patients with varicose veins were treated with the Solutio catheter. All patients in the study reported that pain was minimal, and the Solutio catheter was shown to be safe and effective without complications.

Whilst around 30 per cent of the population suffer from varicose veins, only a small number of patients are treated. Laser treatment is the current leading treatment, but this technique is often painful and involving extensive local anaesthesia (sometimes up to 30 injections through the skin along the vein of the leg to be treated).

MedVasc has high hopes the promising clinical results with Solutio will result in treatment of more patients with varicose veins. Using Solutio reduces the painful insertion of the needle through the skin to only one, minimising the patient pain associated with laser treatment.

Michael Åkesson said: “The results from this study are extremely promising and, in the future, the Solutio technique will be able to solve the problem of pain during laser treatment, and the healthcare system will be able to offer patients the best scientifically proven and most effective technique for treatment of varicose veins.”

MedVasc’s product launch plans:

Sales will involve disposable kits delivered directly to treating clinics and doctors. The product launch is planned for late next year, beginning with the US market, followed by China and the EU.

Relaterade länkar

Ämnen

  • Ekonomi, finans

Kategorier

  • medicon valley life science

Regioner

  • Skåne

Kontakter

Relaterad media

Relaterat innehåll

  • Providing a fast lane to preclinical development

    The past year has been very productive at the relatively small Contract Research Organisation (CRO) Redoxis. Being specialised in preclinical drug development and efficacy evaluation models, Redoxis offers invaluable support to any pharmaceutical drug developer at the very early stages.
    “A lot of CROs tend to focus on the later phases of development, even if they still retain a preclinical app

  • Stem cell product XSTEM in clinical studies

    The Swedish biopharma company Xintela is receiving a lot of attention for its stem cell product platform XSTEMÒand its stem cell therapies in development.
    XSTEM is now in clinical development for the treatment of knee osteoarthritis and difficult-to-heal venous leg ulcers.
    Over the last several years Xintela has worked extensively on preclinical development in three core areas: osteoarthrit

  • Novel treatments for aggressive cancer based on a unique target

    The discovery of the unique target integrin α10β1 may change the outcome of cancer treatment for thousands of patients across the world. Tumor-targeting antibodies for the treatment of aggressive cancers are currently being developed by Targinta, a subsidiary of biopharma company Xintela in Lund.
    Targinta is the oncology subsidiary of the stem cell company Xintela. Both Xintela and Targinta ar

  • Haeger&Carlsson Executive Search is expanding in Medicon Valley

    Haeger & Carlsson has 25 years’ experience of recruitment within Life Science, dating back to 1997 and their vision is to be the leading recruitment company within Life Science in the Nordic region. Haeger & Carlsson sees a huge potential in Medicon Valley and is now opening an office in Copenhagen in addition to the office in Medicon Village, Lund.
    Recruitment is a major investment in

  • Nordic Regulatory experts: Improving biotech chances of Success

    Why is it that so many biotech companies fail? And what are the tools needed to change that fact?
    In order to discuss what to do to increase the chances of success for biotech companies, we met with key experts from LINK Medical. Joining the conversations was Gunnar Danielsson, Senior Regulatory Advisor in Sweden, along with Lone Dyrby, Regulatory Director in Denmark and Hilde K Holme, Regul

  • The splendour of tolerogenic cell therapies

    The biotech company Idogen develops tolerogenic cell therapies to prevent biological drugs, transplanted organs or the body’s own cells or tissue from being attacked by the patient’s immune system.
    Idogen was founded 2008 in Lund, but is today a public company listed on the Nasdaq First North Growth Market. The company has now entered into a very exciting phase where it’s first clinical trial,

Fyll i din epostadress för att följa Affärstidningen Näringsliv

När du väljer att skapa ett konto och följa ett nyhetsrum kommer dina personuppgifter behandlas av oss och av ägaren av nyhetsrummet för att du ska kunna motta nyheter och uppdateringar enligt dina bevakningsinställningar.

För att läsa mer om detta, var vänlig läs vår Integritetspolicy som berör vår behandling av dina personuppgifter, och Integritetspolicy för Contacts som berör behandlingen av dina personuppgifter från ägaren av nyhetsrummet du följer.

Vänligen notera att våra Användarvillkor gäller alla våra tjänster.

Du kan dra tillbaka ditt samtycke när som helst genom att avregistrera dig eller genom att ta bort ditt konto.
Kolla din inkorg

Mejl skickat till __email__. Klicka på länken i mejlet för att följa Affärstidningen Näringsliv.

Okej